Q2 FY2026 · ended Jun 30, 2026 · Revenue $2.05M, -14.9% YoY · Filed Aug 14, 2026
Aspira Women’s Health Inc. (AWHL) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $2.0 million and a net loss of $2.4 million. Free cash flow was -$2.2 million. As of Jun 30, 2026 it held $477,000 in cash and investments and $3.1 million in total debt.
Revenue
$2.05M
-14.9% vs year-ago quarter
Net income
$-2.42M
+9.2% vs year-ago quarter
Operating cash flow
$-2.01M
-15.9% vs year-ago quarter
Free cash flow
$-2.16M
-8.6% vs prior quarter
EPS
$-0.05
+28.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
46.63M
+30.8% vs year-ago quarter
Net cash
$-2.63M
Q2 FY2026
Operating margin
-80.8%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- AWHL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 926617
- Former names
- VERMILLION, INC. (until Jun 10, 2020); CIPHERGEN BIOSYSTEMS INC (until Aug 17, 2007)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $2.0M | $2.2M | $2.3M | $2.4M |
| Operating income | -$1.8M | -$2.2M | -$1.3M | -$1.6M | -$1.8M |
| Net income | -$2.4M | $676,000 | -$3.4M | -$4.9M | -$2.7M |
| Diluted EPS | -$0.05 | -$0.05 | -$0.08 | -$0.13 | -$0.07 |
| Operating cash flow | -$2.0M | -$359,000 | -$2.0M | -$212,000 | -$1.7M |
| Free cash flow | -$2.2M | — | -$2.0M | -$239,000 | — |
| Total assets | $4.4M | $5.1M | $5.5M | $7.3M | $4.9M |
| Total liabilities | $11.7M | $11.3M | $12.4M | $11.6M | $7.6M |
| Stockholders' equity | -$7.3M | -$6.2M | -$6.9M | -$4.3M | -$2.7M |
| Cash and investments | $477,000 | $1.3M | $1.8M | $3.8M | $1.5M |
| Total debt | $3.1M | $4.3M | $3.0M | $2.6M | $2.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 15, 2026 | Jul 6, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 7, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 22, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 9, 2026 | Jun 5, 2026 |
All 1000 Aspira Women’s Health Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.